Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma.

Barney BM, Olivier KR, Miller RC, Haddock MG.

Radiat Oncol. 2012 May 3;7:67. doi: 10.1186/1748-717X-7-67.

2.

Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.

Barney BM, Olivier KR, Macdonald OK, Fong de Los Santos LE, Miller RC, Haddock MG.

Am J Clin Oncol. 2012 Dec;35(6):537-42. doi: 10.1097/COC.0b013e31821f876a.

PMID:
21659830
3.

Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.

Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC.

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):486-93. doi: 10.1016/j.ijrobp.2009.08.020. Epub 2010 Mar 28.

PMID:
20350791
4.

Stereotactic body radiotherapy for unresectable cholangiocarcinoma.

Kopek N, Holt MI, Hansen AT, Høyer M.

Radiother Oncol. 2010 Jan;94(1):47-52. doi: 10.1016/j.radonc.2009.11.004. Epub 2009 Dec 4.

PMID:
19963295
5.

Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.

Osmundson EC, Wu Y, Luxton G, Bazan JG, Koong AC, Chang DT.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):986-94. doi: 10.1016/j.ijrobp.2014.11.028. Epub 2015 Feb 3.

PMID:
25659885
6.

Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients.

Zeng ZC, Tang ZY, Fan J, Zhou J, Qin LX, Ye SL, Sun HC, Wang BL, Li D, Wang JH, Zeng MS, Guo W, Tan YS.

Cancer J. 2006 Mar-Apr;12(2):113-22.

PMID:
16630402
7.

Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy.

Dewas S, Bibault JE, Mirabel X, Fumagalli I, Kramar A, Jarraya H, Lacornerie T, Dewas-Vautravers C, Lartigau E.

Radiat Oncol. 2012 Oct 10;7:166. doi: 10.1186/1748-717X-7-166.

8.

Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.

Makita C, Nakamura T, Takada A, Takayama K, Suzuki M, Ishikawa Y, Azami Y, Kato T, Tsukiyama I, Kikuchi Y, Hareyama M, Murakami M, Fuwa N, Hata M, Inoue T.

Radiat Oncol. 2014 Jan 14;9:26. doi: 10.1186/1748-717X-9-26.

9.

Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA.

J Clin Oncol. 2008 Feb 1;26(4):657-64. doi: 10.1200/JCO.2007.14.3529. Epub 2008 Jan 2. Erratum in: J Clin Oncol. 2008 Aug 10;26(23):3911-2.

10.

Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors.

Ibarra RA, Rojas D, Snyder L, Yao M, Fabien J, Milano M, Katz A, Goodman K, Stephans K, El-Gazzaz G, Aucejo F, Miller C, Fung J, Lo S, Machtay M, Sanabria JR.

Acta Oncol. 2012 May;51(5):575-83. doi: 10.3109/0284186X.2011.652736. Epub 2012 Jan 23.

PMID:
22263926
11.

Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience.

Polistina FA, Guglielmi R, Baiocchi C, Francescon P, Scalchi P, Febbraro A, Costantin G, Ambrosino G.

Radiother Oncol. 2011 May;99(2):120-3. doi: 10.1016/j.radonc.2011.05.016. Epub 2011 May 27.

PMID:
21621289
12.

Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients.

Scorsetti M, Alongi F, Filippi AR, Pentimalli S, Navarria P, Clerici E, Castiglioni S, Tozzi A, Reggiori G, Mancosu P, Ricardi U.

Acta Oncol. 2012 May;51(5):618-23. doi: 10.3109/0284186X.2011.652738. Epub 2012 Jan 23.

PMID:
22263925
13.

The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases.

de Jong MC, Marques H, Clary BM, Bauer TW, Marsh JW, Ribero D, Majno P, Hatzaras I, Walters DM, Barbas AS, Mega R, Schulick RD, Choti MA, Geller DA, Barroso E, Mentha G, Capussotti L, Pawlik TM.

Cancer. 2012 Oct 1;118(19):4737-47. doi: 10.1002/cncr.27492. Epub 2012 Mar 13.

14.

Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.

Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, Fischer R.

Eur J Gastroenterol Hepatol. 2012 Apr;24(4):437-43. doi: 10.1097/MEG.0b013e3283502241.

PMID:
22261548
15.

Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study.

Milano MT, Katz AW, Zhang H, Okunieff P.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):878-86. doi: 10.1016/j.ijrobp.2011.08.036. Epub 2011 Dec 13.

PMID:
22172903
16.

[Stereotactic body radiation therapy for liver primary and metastases: the Lille experience].

Dewas S, Mirabel X, Kramar A, Jarraya H, Lacornerie T, Dewas-Vautravers C, Fumagalli I, Lartigau É.

Cancer Radiother. 2012 Feb;16(1):58-69. doi: 10.1016/j.canrad.2011.06.005. Epub 2011 Dec 30. French.

PMID:
22209710
17.

Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma.

Fu Y, Yang W, Wu W, Yan K, Xing BC, Chen MH.

J Vasc Interv Radiol. 2012 May;23(5):642-9. doi: 10.1016/j.jvir.2012.01.081.

PMID:
22525022
18.

Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins.

Rwigema JC, Heron DE, Parikh SD, Zeh HJ 3rd, Moser JA, Bahary N, Ashby K, Burton SA.

J Gastrointest Cancer. 2012 Mar;43(1):70-6. doi: 10.1007/s12029-010-9203-7.

PMID:
20809393
19.

Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT).

Reyngold M, Wu AJ, McLane A, Zhang Z, Hsu M, Stein NF, Zhou Y, Ho AY, Rosenzweig KE, Yorke ED, Rimner A.

Radiat Oncol. 2013 Apr 25;8:99. doi: 10.1186/1748-717X-8-99.

20.

Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases.

Jiang W, Zeng ZC, Tang ZY, Fan J, Zhou J, Zeng MS, Zhang JY, Chen YX, Tan YS.

J Cancer Res Clin Oncol. 2010 Sep;136(9):1323-31. doi: 10.1007/s00432-010-0783-1. Epub 2010 Feb 4.

PMID:
20130909
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk